Belite Bio, Inc (BLTE): Operating Income
-$84.21M
Year ended 2025-12-31
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$84.21M | n/m | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | -$40.00M | n/m | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | -$31.67M | n/m | 2026-03-31, From 2023-01-01 |
| 2022-12-31 | -$12.82M | n/m | 2025-03-17, From 2022-01-01 |
| 2021-12-31 | -$9.80M | n/m | 2024-03-12, From 2021-01-01 |
| 2020-12-31 | -$5.74M | n/a | 2023-03-31, From 2020-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Belite Bio, Inc (BLTE) | 2025-12-31 | -$84.21M | n/m |
| Spyre Therapeutics, Inc. (SYRE) | 2025-12-31 | -$209.56M | n/m |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | -$215.27M | n/m |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | -$225.68M | n/m |
| MannKind Corp (MNKD) | 2025-12-31 | $38.80M | -46.5% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | -$36.81M | n/m |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $77.22M | n/m |
| Disc Medicine, Inc. (IRON) | 2025-12-31 | -$236.02M | n/m |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | -$270.02M | n/m |
Compare BLTE, SYRE, MRVI, NAMS side by side · Screen every company in Pharmaceutical Preparations ↗